Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec (GLADE)

prof dr Pieter Gillard

Status: Completed

Conditions: Type 1 Diabetes

Treatments: Drug: Insulin Degludec

Study type: Observational

Funder types: Other

Identifiers

NCT05434559

S66239

Details and patient eligibility

About

Retrospective multicenter study analyzing data gathered from medical records and diabetes management platforms to assess the effect of using Insulin Degludec (Tresiba®) on measures of diabetes control.

People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 will be included.

Glycemic control from 12 months before the switch to Insulin Degludec will be compared to glycemic control of the 12 months after the switch.

Enrollment: 475 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• People with T1D ≥18 years at the moment of switch to Insulin Degludec
• Diagnosed with T1D ≥2 years before switch to Insulin Degludec
• On basal-bolus insulin therapy with insulin pens ≥2 years before switch to Insulin Degludec
• ≥6 months use of Insulin Degludec at moment of datacollection
• Using continuous glucose monitoring ≥2 years before switch to Insulin Degludec

Exclusion criteria

• People with T1D <18 years at the moment of switch to Insulin Degludec
• People without T1D or with T1D <2 years before switch to Insulin Degludec
• Women with T1D who are pregnant or planning pregnancy during -12 and +12 months
• Not using basal-bolus insulin therapy with insulin pens during -24 and +6 months
• Start to use non-insulin antidiabetic agents between -12 and +12 months
• Having received treatment with oral or injectable corticosteroids during -12 and +12 months
• Undergoing hemodialysis, renal transplantation, or beta cell transplantation during -12 and +12 months
• <6 months use of Insulin Degludec at moment of datacollection
• Not using continuous glucose monitoring or <2 years before switch to Insulin Degludec

Trial design

475 participants in 1 patient group

Study cohort

Description:

People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 in the two participating sensors

Treatment:

Drug: Insulin Degludec